Clinical Recruitment
Oncolytic viruses are a class of anti-cancer agents that selectively replicate within tumor cells, inducing tumor cell lysis and eliciting anti-tumor immune responses. VRT106 for injection, developed by Guangzhou Virotech Pharmaceutical Co., Ltd., demonstrates selective infection and replication in tumor cells. Its anti-tumor activity is mediated through multiple mechanisms, including endoplasmic reticulum stress-induced apoptosis, cytokine-mediated bystander cell death, and immune cell-mediated cytotoxicity, while sparing normal cells. Multiple Phase I clinical trials have been initiated in both China and Japan.
Focus on us
Contact Information
Monday to Friday 9:00~17:00
Rooms 801-808 and 901-908, Building H, No. 3 Jiu Quan Road, Huangpu District, Guangzhou City
Copyright©2024 Virotech Pharmaceutical Technology Co., Ltd.
